SWOG clinical trial number
CTSU/NRG-BR007
A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Open
Phase
Abbreviated Title
Ph III Evaluation of De-escalation of Radiation for Stage I, Hormone Sensitive HER2-, Treatment of Stage I, Hormone Sensitive, HER2- Oncotype Recurrence Score </=18
Status Notes
CTSU/NRG-BR007 has been endorsed and activated by SWOG, effective 6/15/2021. CTSU/NRG-BR007 was activated by NRG Oncology, effective 6/7/21.
Activated
06/07/2021
Research committees
Breast Cancer
Eligibility Criteria Expand/Collapse
Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org).
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/NRG-BR007
A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase
SWOG Clinical Trial Number
CTSU/A011801
The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in Her2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
01/06/2021
Open
Phase
SWOG Clinical Trial Number
S2007
A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Research Committee(s)
Breast Cancer
Activated
12/15/2020
Accrual
43%
Open
Phase